We summarize the current clinical landscape and outline therapies that have shown limited efficacy in TP53 mutant AML, including induction chemotherapy, venetoclax plus azacitidine (VenAza), allo-HSCT, and multiple investigational agents. This evidence concerns the gene TP53 and acute myeloid leukemia.